HomeMarketsSharesCentessa Pharmaceuticals Limited

Trade Centessa Pharmaceuticals Limited - CNTA CFD

40.48+0.12%
The chart shows the CNTA stock price data over the last 1 day, with a current price of 40.6, a high of 40.48, and a low of 39.99.
Low: 39.99High: 40.48
Sellers:
100%
Buyers:
0%
Past performance is not a reliable indicator of future results. Share prices are indicative and may differ from live market prices.
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.12
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.02149 %
(-$0.43)

Trade size with leverage ~ $2,000.00

Money from leverage ~ $$1,000.00


-0.02149%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.00074 %
(-$0.01)

Trade size with leverage ~ $2,000.00

Money from leverage ~ $$1,000.00


-0.00074%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity1
Margin50.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close40.1
Open39.99
1-Year Change221.98%
Day's Range39.99 - 40.48

Trade Centessa Pharmaceuticals Limited - CNTA

Centessa Pharmaceuticals Limited (NASDAQ: CNTA) is a U.K.-based biotech company operating a unique decentralized R&D model across multiple subsidiaries targeting rare and specialty diseases. Its pipeline includes candidates in hematology, immunology, and oncology, with a focus on asset-centric development efficiency. Backed by life sciences investors, Centessa aims to streamline drug discovery while de-risking capital deployment. It offers investors a diversified, early-stage biotech platform with program-level optionality and clinical momentum.

Latest shares articles

What you need to know about Alphabet after the biggest one-day drop in its history – break-down
Google Cloud is growing fast, but AI spending pushed Alphabet’s free cash flow negative. A full break-down of results, valuation, debt and risks for GOOGL
11:53, 13 November 2026
Amazon's USD 220bn bet: how record AI spending could reshape the company
Amazon plans about USD 220bn of capex in 2026. We look at AWS, profitability, debt, valuation and the key catalysts and risks for AMZN shares.
10:50, 6 November 2026
Wall Street sign beside the marble facade of the New York Stock Exchange building, with American flags flying from the exterior
US midterms: the end of uncertainty could give Wall Street direction
Markets dislike uncertainty and volatility tends to rise ahead of the vote, but once the results are known, indices may be able to set a clearer direction.
13:28, 29 October 2026
BAE Systems stock forecast
BAE Systems stock forecast: H1 results, guidance upgrade
BAE Systems is a UK defence and aerospace group listed in London. In August 2026, it secured a $149.8m US Navy award for work on the USS Boxer. Explore third-party BA. price targets and technical analysis. Past performance is not a reliable indicator of future results.
07:18, 16 October 2026

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready